CN114539382A - Polypeptide and cryopreservation liquid containing polypeptide - Google Patents
Polypeptide and cryopreservation liquid containing polypeptide Download PDFInfo
- Publication number
- CN114539382A CN114539382A CN202210043367.6A CN202210043367A CN114539382A CN 114539382 A CN114539382 A CN 114539382A CN 202210043367 A CN202210043367 A CN 202210043367A CN 114539382 A CN114539382 A CN 114539382A
- Authority
- CN
- China
- Prior art keywords
- cryopreservation
- polypeptide
- solution
- cells
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a polypeptide and cryopreservation liquid containing the polypeptide, wherein the polypeptide is a functional region of LEA protein, has good biocompatibility in aqueous solution, and is an ideal ice control material. The cryopreservation solution containing the polypeptide has high survival rate when being used for cryopreservation of various cells, can only achieve the effectiveness of freezing various cells by using a conventional cryopreservation solution, and is equivalent to the recovery rate of cryopreservation of a commercial cryopreservation solution containing 10% DMSO and commonly used at present.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a polypeptide, a cryopreservation liquid containing the polypeptide, and applications of the polypeptide and the cryopreservation liquid containing the polypeptide.
Background
Cryopreservation refers to keeping the biological material at ultralow temperature to slow down or stop cell metabolism and division, and to continue to develop once normal physiological temperature is restored. The development of modern medicine has gone through chemical drugs, biological drugs, and has advanced to cellular drugs. However, cells cultured in vitro (ex vivo) undergo replicative senescence and death. Therefore, the 'cells' become the medicines which are taken and used on the shelf, and the storage problem needs to be solved firstly. As the only technology which is expected to realize long-term storage and remote transportation of the cells at present, cryopreservation becomes an indispensable technical support for cell therapy. In general, in the process of cell cryopreservation, cryopreservation reagents are required to be added to protect the cells from freezing damage. Therefore, cryopreservation reagents are the key material basis for determining the success of cryopreservation.
The most commonly used cryopreservation reagent at present is a vitrified cryopreservation reagent which contains a large amount of small molecules with strong hydration, such as dimethyl sulfoxide (DMSO is more than or equal to 10%), and the addition of DMSO can inhibit the formation of ice crystals during cryopreservation (liquid inside and outside cells is in a vitrified state to avoid the formation of the ice crystals). However, DMSO has cytotoxicity, enzyme toxicity and the like, which cause toxic and side effects of the cryopreservation reagent on cells, and seriously affect the biosafety and even the functional expression of the cryopreserved objects after resuscitation.
TABLE 1 conserved domains of LEA proteins 1-4 and 6-7
However, many organisms in nature are protected from freezing damage by the presence in the body of stress-resistant proteins that can withstand extreme environmental stresses, allowing them to survive in low temperature environments of-30 or even 50 degrees celsius. For example, a class of stress-resistant proteins that are widely found in organisms that live in arid and cold environments, namely: late embryonic development Abundant Protein (Late embryo growth Absundant Protein), abbreviated LEA Protein. When an organism is stressed by environment (such as low temperature, drought, salt strain and the like), the normal metabolic activity of the organism is maintained along with the accumulation and expression of LEA protein. For example, when plants are stressed by water and low temperature, the LEA protein can be highly expressed in vivo to prevent the plants from being damaged by freezing and drought; overexpression of the LEA protein in an organism may be to enhance its resistance to low temperature and osmotic stress. LEA proteins are divided into 7 families, and except five families of LEA proteins, the other 6 families of LEA proteins all have more than 1 conserved structural domain consisting of sequences of a plurality of amino acids (more than or equal to 4) (table 1), and the conserved structural domain can have a plurality of copies in organisms and plays an important role in maintaining the stress resistance function of the LEA proteins. Organisms in the nature do not depend on DMSO (dimethyl sulfoxide) which is a strongly hydrated small molecule to resist freezing damage, and a new idea is provided for designing and preparing stress-resistant materials capable of resisting ice crystals and osmotic pressure generated by the ice crystals in a freezing storage process. The synthesis of the conserved domain of the LEA protein is simple and is an important guarantee that the LEA protein maintains the stress resistance function, so the patent designs and prepares the conserved domain of the LEA protein for the first time and characterizes the effect of the conserved domain in the application of cryopreservation of different types of cells. At present, no commercial cryopreservation solution and application for cryopreserving various cells by using the conserved domain of the LEA protein as a cryoprotectant exist.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a LEA protein conserved structural domain, which is hereinafter referred to as a polypeptide of a LEA protein functional region, a cryopreservation solution containing the polypeptide, and applications of the polypeptide and the cryopreservation solution containing the polypeptide.
The invention is realized by the following technical scheme:
the invention provides a polypeptide, which is characterized in that the polypeptide comprises an amino acid sequence of a functional region of an LEA protein, or an active fragment, analogue or derivative of the polypeptide. Preferably, the polypeptide is a functional region of a LEA protein.
According to the invention, the polypeptide is selected from at least one group of the following a) to c):
a) having the amino acid sequence shown in table 1;
b) a derivative polypeptide which is formed by deleting or adding one or more amino acids from both ends of a polypeptide having an amino acid sequence shown in Table 1 and has a) a function of the polypeptide; or
c) The homology is higher than 90% compared to the polypeptides of the amino acid sequences shown in table 1.
According to the invention, preferably said c) has a homology of between 90 and 99%, such as 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% compared to the polypeptides of the amino acid sequences shown in table 1.
According to the present invention, preferably, the amino acid sequence of said polypeptide is as shown in table 1.
More preferably, according to the present invention, the amino acid sequence of said polypeptide is as shown in table 2.
The present invention also provides a polynucleotide characterized in that the polynucleotide comprises one selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide having an amino acid sequence set forth in table 1, or a fragment, analog, derivative thereof;
(b) a polynucleotide complementary to polynucleotide (a); or
(c) A polynucleotide having at least 70% homology to (a) or (b).
According to the invention, in said c) the homology is between 70 and 99%, such as 70%, 71%, 72%, 75%, 78%, 80%, 81%, 82%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% compared to the polynucleotide of (a) or (b).
According to the present invention, preferably, the polynucleotide comprises a polynucleotide encoding an amino acid sequence shown in table 1.
More preferably, according to the present invention, said polynucleotide encodes a polypeptide as shown in table 1.
More preferably, according to the present invention, said polynucleotide encodes a polypeptide as shown in table 2.
The invention also provides a preparation method of the polypeptide, which can be synthesized by a polypeptide synthesis method known in the field, such as a solid phase synthesis method.
The invention also provides the application of the polypeptide in the cryopreservation of cells, tissues or organs.
According to the application of the invention, the polypeptide can be combined with other ice control materials, and the other ice control materials are at least one of amino acid monomers, polyamino acid, saccharides and the like.
The invention also provides a cryopreservation solution containing the polypeptide.
The cryopreservation solution according to the present invention contains 0.1 to 50g of the polypeptide per 100 mL. Preferably, it contains 0.1 to 20g of the polypeptide, more preferably 0.2 to 10g of the polypeptide, still more preferably 0.5 to 8g of the polypeptide, and still more preferably 1 to 5g of the polypeptide.
The cryopreservation solution of the present invention may further comprise one or more of amino acid monomers, polyamino acids, saccharides, DMSO, and polyhydric alcohols.
According to the present invention, the amino acid monomer may be at least one or more selected from lysine, arginine, proline, threonine, histidine, and the like. Preferably, the amino acid monomer is proline, more preferably, the amino acid monomer is L-Pro.
According to the present invention, the polyamino acid may be selected from at least one homopolymer of lysine, arginine, proline, threonine, histidine, and the like, or a copolymer of two or more amino acids. Preferably, the polyamino acid is polyproline 8. More preferably, the polyamino acid is L-Pro8 (i.e., a polyproline having a degree of polymerization of 8).
According to the invention, the polyol may be a polyol having from 2 to 6 carbon atoms, such as a polyol having from 2 to 5 carbon atoms, preferably a diol having from 2 to 3 carbon atoms, and/or a triol, such as any of ethylene glycol, propylene glycol, glycerol; ethylene glycol is preferred.
According to the cryopreservation liquid of the present invention, the saccharides are polyhydroxy aldehydes, polyhydroxy ketones, and organic compounds that can be hydrolyzed to generate polyhydroxy aldehydes or polyhydroxy ketones, and can be classified into monosaccharides, disaccharides, polysaccharides, and the like. They can be classified into water-insoluble saccharides or water-soluble saccharides, such as monosaccharides, disaccharides or polysaccharides, depending on their water-soluble characteristics. Preferably, the saccharide is a water-soluble saccharide. More preferably, the saccharide is glucose and sucrose.
According to the present invention, the water-soluble saccharide may be at least one of non-reducing disaccharide, water-soluble polysaccharide, and anhydrosugar, and is selected from sucrose, glucose, trehalose, water-soluble cellulose (e.g., hydroxypropylmethyl cellulose, etc.), polysucrose; sucrose, glucose, hydroxypropyl methylcellulose are preferred. The water-soluble sugar can play a role in protecting cell membranes and avoiding cell sedimentation.
The cryopreservation solution of the present invention may further contain a buffer solution.
According to the present invention, the buffer may be selected from at least one of DPBS or hepes-buffered buffers, or other cell culture medium buffers.
The cryopreservation solution of the present invention may further contain serum.
According to the invention, the serum may be selected from human serum albumin or analogues thereof, such as Sodium Dodecyl Sulphate (SDS); fetal bovine serum or bovine serum albumin can be selected for the non-human-derived cryopreservation object.
The cryopreservation solution comprises 0.1-50g of the polypeptide, 0-9.0g of amino acid or polyamino acid, 0-15mL of DMSO, 5.0-45mL of polyalcohol and 0.1-1.0mol L per 100mL-10-30mL of serum, and the balance of buffer solution.
The cryopreservation solution according to the present invention contains 0.1 to 20g of the polypeptide, preferably 0.2 to 10g of the polypeptide, more preferably 0.5 to 8g of the polypeptide, and still more preferably 1 to 5g of the polypeptide per 100 mL.
The cryopreservation solution according to the present invention contains an amino acid or a polyamino acid. Preferably, the amino acid or polyamino acid is 0.1-8g per 100 mL; more preferably, from 0.5 to 6 g; or 0.8 to 5g, still more preferably 1 to 4g, or 2 to 3 g.
The cryopreservation solution according to the present invention preferably does not contain DMSO, but may contain DMSO. The DMSO is not higher than 15mL, preferably not higher than 10mL per 100 mL; more preferably not higher than 7.5mL, and may be not higher than 5mL, or not higher than 2.5 mL.
The cryopreservation solution of the present invention contains 5.0 to 45mL of a polyhydric alcohol per 100 mL. Or 6-40mL of polyhydric alcohol, and also can be 8-30mL of polyhydric alcohol; for example, 10 to 25mL of polyol, or 10 to 15mL of polyol, or 15 to 20mL of polyol.
The cryopreservation solution according to the present invention is 0.1 to 1.0mol L per 100mL-1The water-soluble sugar of (1). For example, it may be in the range of 0.2 to 0.8mol L-1The water-soluble sugar of (1); 0.3-0.7mol L-10.5-0.6mol L of water-soluble sugar-1The water-soluble sugar of (1).
The cryopreservation solution of the present invention is 0 to 30mL of serum per 100 mL. Preferred protocols may not use serum. But serum may also be used. The amount of serum may be 2-25mL, alternatively 5-20mL, alternatively 10-15 mL.
In a specific embodiment of the present invention, the cryopreservation solution comprises 1.0g of the polypeptide, 10 to 15mL of ethylene glycol, and 0.5mol L per 100mL of the cryopreservation solution-1Sucrose and the balance of buffer solution.
In one embodiment of the present invention, the cryopreservation solution comprises 0.5g of the polypeptide, 0.8 to 1.0g of L-Pro, 10mL of ethylene glycol, and 0.5mol of L per 100mL of the cryopreservation solution-1The balance being buffer solution.
In one embodiment of the present invention, the cryopreservation solution comprises 0.5g of the polypeptide, 0.8 to 1.0g of L-Pro8, 10mL of ethylene glycol, and 0.5mol of L per 100mL of the cryopreservation solution-1The balance being buffer solution.
In one embodiment of the present invention, the cryopreservation solution comprises 0.5g of the polypeptide, 1.0g of glucose, 10mL of ethylene glycol, and 0.5mol L per 100mL of the solution-1The balance being buffer solution.
The invention also provides a preparation method of the cryopreservation liquid, which comprises the steps of dissolving the polypeptide in a buffer solution, adjusting the pH after cooling to room temperature, dissolving other components in another buffer solution, mixing after cooling, adjusting the pH, fixing the volume to a preset volume by using the buffer solution, and optionally adding serum when in use.
The preparation method comprises the following steps:
(1) dissolving polypeptide in a part of buffer solution, cooling to room temperature, and adjusting pH to obtain a solution 1;
(2) dissolving water-soluble sugar in a part of buffer solution, and adding other components after the water-soluble sugar is completely dissolved to prepare a solution 2;
(3) optionally, dissolving amino acid and/or saccharide in another part of buffer solution, cooling to room temperature, and adjusting pH to obtain solution 3;
(4) and (3) cooling the solution 1, the solution 2 and optionally the solution 3 to room temperature, mixing, adjusting the pH value, and fixing the volume to a preset volume by using a buffer solution to obtain the cryopreservation solution.
The invention also provides a cryopreservation method for performing cryopreservation on different types of cells by using the cryopreservation liquid.
According to the present invention, preferably, the cryopreservation method comprises the steps of: and (3) placing the cells to be cryopreserved in the cryopreservation liquid for a period of time, and then placing the cells in a liquid nitrogen environment for cryopreservation.
According to the present invention, more preferably, the cryopreservation may employ both a slow cooling method and a fast cooling method. The slow cooling comprises the steps of placing the cell (tissue) freezing solution mixture in a room temperature environment for balancing for 10-30min, placing the cell (tissue) freezing solution mixture in a program cooling box or a program cooling instrument, slowly cooling by a program of 1 ℃/min, and transferring the cell (tissue) freezing solution mixture into liquid nitrogen for long-term storage when the temperature is reduced to-80 ℃. The rapid cooling comprises placing the cells (tissues) in the frozen stock solution for 5-15min, and rapidly placing in liquid nitrogen to cool the cells to-196 ℃ in a short time.
According to the present invention, preferably, the cryopreservation method further comprises thawing: taking out the frozen cells and tissues from the liquid nitrogen environment, and quickly putting the cells and tissues into a water bath at 37 ℃ for thawing. Thawed cells, tissues are washed with culture medium or PBS and transferred to a suitable culture environment as soon as possible.
The invention also provides application of the cryopreservation liquid in cryopreservation of various cells, tissues and organs.
According to the use and cryopreservation of the invention, the cells, tissues and organs are any cells, tissues and organs suitable for cryopreservation. Wherein the cells comprise the following human or animal cells: stem cells, engineered cells, cell lines, somatic cells, germ cells, blood cells, immune cells, tumor cells, and the like; including the following human or animal tissues: skin tissue, connective tissue, adipose tissue, neural tissue, cardiac tissue, pancreatic islet tissue, ovarian tissue, testicular tissue, placental tissue, umbilical cord tissue.
According to the invention, the engineering cell is a cell which is obtained by modifying or recombining genetic materials of a host cell by adopting a genetic engineering technology or a cell fusion technology and has unique characters of stable heredity.
According to the invention, the cell line refers to the cells after the first subculture of the primary culture, i.e. the cell line. Including limited cell lines of limited life span and continuous or unlimited cell lines that have acquired unlimited reproductive capacity to survive continuously.
According to the present invention, preferably, the stem cells are various stem cells having a differentiation function known in the art, including pluripotent stem cells, multipotent stem cells, and multipotent stem cells. Including but not limited to embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, mesenchymal stem cells, neural stem cells, and the like. Preferably, the mesenchymal stem cell is umbilical cord mesenchymal stem cell, umbilical cord blood mesenchymal stem cell, bone marrow mesenchymal stem cell, placenta mesenchymal stem cell, adipose mesenchymal stem cell, dental pulp mesenchymal stem cell.
According to the present invention, preferably, the stem cell is a human bone marrow mesenchymal stem cell derived from human bone marrow and can be isolated from human bone marrow according to a known clinical application method.
According to the present invention, preferably, the engineered cell may be selected from Chinese Hamster Ovary cells (Chinese Hamster Ovary).
According to the present invention, preferably, the cell line is bovine kidney cells (MDBK).
According to the invention, preferably, the cell lines are human acute T-lymphocyte leukemia cells (E6-1 cells).
According to the invention, the cryopreservation liquid is preferably used for cryopreservation of stem cells, and is exemplarily used for cryopreservation of human mesenchymal stem cells.
Exemplary, e.g., for cryopreservation of engineered cells, cell lines.
Advantageous effects
The inventor of the invention finds the functional region of the LEA protein, and further experiments prove that the LEA protein has the function of cryoprotection on various cells, tissues or organs, and the cryopreservation reagent based on the protein functional region of the LEA not only can achieve the effectiveness of various cells such as stem cells, engineering cells, cell lines and the like of the conventional cryopreservation liquid, but also is equivalent to (without statistical difference) the cryopreservation recovery rate of the currently and generally used commercialized cryopreservation liquid containing 10% of DMSO (dimethyl sulfoxide), and even exceeds the survival rate of the commercialized cryopreservation reagent. LEA protein has excellent biocompatibility, has no toxicity to human and animal cells, can protect cells from cell damage caused by adverse circumstances, and has the function of stabilizing cell membranes.
Detailed Description
The preparation method of the present invention will be described in further detail with reference to specific examples. It is to be understood that the following examples are only illustrative and explanatory of the present invention and should not be construed as limiting the scope of the present invention. All the techniques realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, materials and the like used in the following examples are commercially available unless otherwise specified.
Example 1LEA protein functional region Polypeptides
TABLE 2LEA protein domains
| Reference numerals | Amino acid sequence | Name (R) | Molecular weight (D) |
| LS 1-1 | RAEQLGHEGYQEMGQKGGQ | LEA1-F | 2103.27 |
| LS 2-1 | EKKGIMDKIKEKLPG | LEA2-K | 1714.11 |
| LS 2-2 | SSSSSEDD | LEA2-S | 812.7 |
| LS 2-3 | RTDEYGNPVH | LEA2-Y | 1187.24 |
The present invention was further studied by solid phase synthesis, taking the LEA protein functional domains in table 2 as an example.
Example 2LEA protein functional region polypeptide frozen mesenchymal Stem cells
1. Materials:
mesenchymal stem cells: purchased from beijing betais biotechnology limited;
commercial vitrified cryopreservation solution containing 10% DMSO: purchased from Beijing Baicao Take Biotech Ltd.
2. Method for producing a composite material
(1) Preparation of cryopreservation solution and comparative example
Cryopreservation liquid 1(lea 1-F):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| Lea1-F(g) | 1.0 |
| Ethylene glycol (mL) | 10 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Freeze preservation solution 2(lea 2-K):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| Lea2-K(g) | 1.0 |
| Ethylene glycol (mL) | 10 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Allowance of |
Cryopreservation liquid 3(lea 2-S):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
cryopreservation liquid 4(lea 2-Y):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| Lea2-Y(g) | 1.0 |
| Ethylene glycol (mL) | 10 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Preparation of a cryopreservation liquid: dissolving 1.0g of functional region polypeptide in 30mL of DPBS (double stranded chain bacillus) by magnetic stirring, and adjusting the pH value to 7.0 to obtain a solution 1 after completely dissolving and cooling to room temperature; 17g (0.05mol) of sucrose (sucrose in a final concentration of 0.5mol L in the cryopreservation solution)-1) Ultrasonically dissolving the mixture in 40mL of DPBS, adding 10mL of glycol to obtain a solution 2 after all the sucrose is dissolved, mixing the two solutions when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Comparative example: frozen preservation solution 1 #: vitrified cryopreservation solutions containing 10% DMSO were commercialized.
(2) The mesenchymal stem cells are preserved by using the cryopreservation liquid and the formula of the comparative example
Freezing and storing cells:
the stem cells in a 10cm dish were digested with 0.25% trypsin at 37 ℃ for 1min, when the cells were dispersed into single cells and partially detached from the dish, neutralized by adding 4 times the volume of complete medium (a-MEM + 10% FBS), blown up until the cells were completely detached from the dish, transferred to a 15mL centrifuge tube, and centrifuged at 1200rpm for 5 min. The supernatant was discarded and MSC cells were resuspended using 1mL DPBS. Cell counting and cell viability assays were performed using a cytometer. The number of cryopreserved cells in each centrifuge tube was 5 x 105And (4) respectively. The cell suspension was transferred to a cryopreservation tube (about 200. mu.L) according to the number of cells, and the cryoprotectant solution to be tested was added to the tubes respectively until the total volume was 400. mu.L. Blowing, beating, mixing, placing the freezing tube into a program cooling box, and freezing in a refrigerator at-80 deg.C overnight. Taking out the frozen tube the next day, and transferring the tube into a liquid nitrogen tank.
Thawing the stem cells:
the cryopreserved human bone marrow-derived Mesenchymal Stem Cells (MSCs) were taken out from the liquid nitrogen tank, immediately placed in a water bath at 37 ℃ and shaken in the water bath to rapidly thaw the cells within 1 min. The thawed cell suspension was then added to 4 volumes of complete medium (a-MEM + 10% FBS), then transferred to a 15mL centrifuge tube and centrifuged at 1200rpm for 5 min. The supernatant was discarded and the cells were resuspended using 500. mu.L of PBS. Cell counting and cell viability assays (viability: number of viable cells/total cells 100) were performed using a cytometer. Then cells were seeded into 96-well plates, 10000 cells per well (6 groups of human bone marrow-derived mesenchymal stem cell samples cryopreserved with cryoprotectants of each concentration were seeded in parallel); and a fresh cell group was made for normal passage without undergoing cryopreservation recovery.
3. Results and conclusions
TABLE 3 survival rate of cryopreserved mesenchymal stem cells
| Numbering | Cryopreservation liquid | Survival rate% |
| Lea1-F | Cryopreservation liquid 1 | 85.6 |
| Lea2-K | Cryopreservation liquid 2 | 81.8 |
| Lea2-S | Cryopreservation liquid 3 | 82.1 |
| Lea2-Y | Cryopreservation liquid 4 | 80.1 |
| Comparative example | Cryopreservation liquid 1# | 85.4 |
The results in table 3 show that, when the cryopreservation solution of the present invention is used for cryopreservation of human umbilical cord mesenchymal stem cells, the survival rate of the human umbilical cord mesenchymal stem cells can reach more than 80% even without DMSO, and even when DMSO and serum are not added at all, the survival rate can reach 85.6%, which reaches the survival rate of the existing cryopreservation reagent, which indicates that the cryopreservation reagent based on the protein functional region of LEA can not only reach the effectiveness of the conventional cryopreservation solution for lyophilized cells, but also is equivalent to the recovery rate (no statistical difference) of the currently and widely used commercialized cryopreservation solution containing 10% DMSO.
Example 3 Complex use of LEA protein functional region polypeptide and Ice control Material
1. Materials:
mesenchymal stem cells; purchased from beijing botaisi biotechnology limited;
commercial vitrified cryopreservation solution containing 10% DMSO: purchased from biotechnology limited of Baicao Taike, Beijing.
2. Method of producing a composite material
(1) Preparation of cryopreservation fluid and comparative example
Cryopreservation liquid 5(lea 1-F):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| lea1F(g) | 0.5 |
| Ethylene glycol (mL) | 10 |
| L-Pro(g) | 1.0 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
The preparation method comprises the following steps: dissolving 0.5g of functional region polypeptide completely, cooling to room temperature, and adjusting the pH value to 7.0 to obtain a solution 1; 1.0g of L-Pro and 17g (0.05mol) of sucrose (sucrose in a final concentration of 0.5mol L in the cryopreservation solution)-1) Ultrasonically dissolving the mixture in 50mL of DPBS, adding 10mL of ethylene glycol to obtain a solution 2 after all the sucrose is dissolved, mixing the two solutions when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Freeze preservation solution 6(lea 2-K):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| LEA2K(g) | 0.5 |
| Ethylene glycol (mL) | 10 |
| L-Pro 8 | 0.8 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
The preparation method comprises the following steps: dissolving 0.5g of functional region polypeptide completely, cooling to room temperature, and adjusting the pH value to 7.0 to obtain a solution 1; 0.8g of polyproline 8(L-Pro8) and 17g (0.05mol) of sucrose (sucrose in a final concentration of 0.5mol L in the cryopreservation solution-1) Ultrasonically dissolving the mixture in 50mL of DPBS, adding 10mL of ethylene glycol to obtain a solution 2 after all the sucrose is dissolved, mixing the two solutions when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Cryopreservation liquid 7(lea 2-S):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
dissolving 0.5g of functional region polypeptide, cooling to room temperature, and adjusting the pH value to 7.0 to obtain a solution 1; 1.0g of glucose and 17g (0.05mol) of sucrose (sucrose in a final concentration of 0.5mol L in the cryopreservation solution)-1) Ultrasonically dissolving the mixture in 50mL of DPBS, adding 10mL of glycol as a solution 2 after all sucrose is dissolved, mixing the two solutions uniformly when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Cryopreservation liquid 8(lea 2-Y):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| lea2Y(g) | 0.5 |
| Ethylene glycol (mL) | 10 |
| Glucose (g) | 1.0 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Dissolving 0.5g of functional region polypeptide completely, cooling to room temperature, and adjusting the pH value to 7.0 to obtain a solution 1; 1.0g of glucose and 17g (0.05mol) of sucrose (sucrose in a final concentration of 0.5mol L in the cryopreservation solution)-1) Ultrasonically dissolving the mixture in 50mL of DPBS, adding 10mL of ethylene glycol to obtain a solution 2 after all the sucrose is dissolved, mixing the two solutions when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Comparative example: frozen preservation solution 1 #: vitrified cryopreservation solutions containing 10% DMSO were commercialized.
(2) The mesenchymal stem cells are preserved by using the cryopreservation liquid and the formula of the comparative example
Detailed cell cryopreservation and cell lyophilization are described in example 2.
3. Results and conclusions
TABLE 4 survival rate of cryopreserved mesenchymal stem cells
| Number of | Cryopreservation liquid | Survival rate% |
| Cryopreservation liquid 5 | 90.1 | |
| Cryopreservation liquid 6 | 85.6 | |
| Cryopreservation liquid 7 | 86.3 | |
| Cryopreservation liquid 8 | 85.2 | |
| Comparative example | Cryopreservation liquid 1# | 85.4 |
According to the results in table 4, it can be seen that the cryopreservation solution prepared by using the LEA functional domain polypeptide as the main component has a high survival rate when used for cryopreservation of stem cells, which indicates that the LEA-based cryopreservation reagent for protein functional domain not only can achieve the effectiveness of conventional cryopreservation solution for lyophilized cells, but also is equivalent to the recovery rate (no statistical difference) of currently and commonly used commercial cryopreservation solution containing 10% of DMSO, and the survival rate (P <0.05) of commercial cryopreservation reagent is even exceeded by compounding the LEA functional domain polypeptide with L-Pro.
Therefore, the cryopreservation liquid prepared by taking the LEA functional region polypeptide as the main component is used for cryopreservation of stem cells, can achieve good cell survival rate and biological activity, and can be used together with other ice control materials, wherein the survival rate of the stem cells subjected to cryopreservation is highest when the LEA functional region polypeptide is used together with L-Pro.
Example 4 application of LEA protein functional region Polypeptides in engineered cell cryopreservation
1. Material
Chinese hamster ovary cells (CHO cells): purchased from north nano institute of innovation, biotechnology limited;
commercial vitrified cryopreservation solution containing 10% DMSO: purchased from Beijing Baicao Take Biotech Ltd.
2. Method of producing a composite material
(1) Preparation of cryopreservation solution and comparative example
Cryopreservation liquid 9(lea 1-F):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (c) of |
| Lea1-F(g) | 1.0 |
| Ethylene glycol (mL) | 15 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Freeze preservation solution 10(lea 2-K):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (c) of |
| Lea2-K(g) | 1.0 |
| Ethylene glycol (mL) | 15 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Cryopreservation liquid 11(lea 2-S):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
cryopreservation liquid 12(lea 2-Y):
the cryopreservation solution is prepared according to the following formula, and each 100mL of the cryopreservation solution contains the following components:
| substance(s) | Content (wt.) |
| Lea2-Y(g) | 1.0 |
| Ethylene glycol (mL) | 15 |
| Sucrose (mol L)-1) | 0.5 |
| DPBS(mL) | Balance of |
Preparation of a cryopreservation solution: 1.0g of functional region polypeptide is dissolved in 30mL of DPBS by magnetic stirring, and after the functional region polypeptide is completely dissolved and cooled to room temperature, the pH value is adjusted to 7.0 to obtain a solution 1; 17g of (0.05mol) of sucrose (the final concentration of sucrose in the cryopreservation solution is 0.5mol L-1) Ultrasonically dissolving the mixture in 40mL of DPBS, adding 15mL of ethylene glycol as a solution 2 after all sucrose is dissolved, mixing the two solutions uniformly when the solution 1 and the solution 2 return to room temperature, adjusting the pH value, and fixing the volume to make up the balance to the total volume.
Comparative example: frozen preservation solution 1 #: vitrified cryopreservation solutions containing 10% DMSO were commercialized.
(2) Preservation of Chinese hamster ovary cells Using the cryopreservation fluid and comparative example formulation
Freezing and storing cells:
chinese hamster ovary Cells (CHO) in T75 flasks were gently pipetted to separate into single cells and transferred to a 15mL centrifuge tube and centrifuged at 1400rpm for 5 min. The supernatant was discarded and the CHO cells were resuspended using 3mL DPBS. Cell counting and cell viability assays were performed using a cytometer. 250 microliter of cryopreservation liquid to be tested, a certain amount of DPBS (250 microliter-cell suspension) and 5 multiplied by 10 cell number are added into each cryopreservation tube5The cell suspension (about 140 mu L) of each cell, the total volume of which is 500 mu L, is blown and evenly mixed, the freezing tube is put into a program cooling box and is frozen in a refrigerator at minus 80 ℃ for 7 hours, then the freezing tube is taken out and is transferred into a liquid nitrogen tank.
Cell recovery:
the above cryopreserved CHO cells were removed from the liquid nitrogen tank, immediately placed in a 37 ℃ water bath, and shaken in the water bath to rapidly thaw the cells within 3 min. The thawed cell suspension was then removed and subjected to cell counting and cell viability assay (viability: number of viable cells/total cells x 100) using a cell counter.
3. Results and conclusions
TABLE 5 Chinese hamster ovary cell cryopreservation survival rates
| Numbering | Cryopreservation liquid | Survival rate% |
| Cryopreservation liquid 9 | 77.1 | |
| Cryopreservation liquid 10 | 78.2 | |
| Cryopreservation liquid 11 | 76.8 | |
| Cryopreservation liquid 12 | 82.2 | |
| Comparative example | Cryopreservation liquid 1# | 78.7 |
As can be seen from the results in table 5, the cryopreservation solution prepared from the LEA functional domain polypeptide as the main component has a high survival rate when used for cryopreservation of engineered cells, which indicates that the cryopreservation reagent based on the LEA protein functional domain not only can achieve the effectiveness of conventional cryopreservation solution cryopreservation engineered cells, but also has a recovery rate (no statistical difference) comparable to that of currently and commonly used commercial cryopreservation solution containing 10% DMSO, and even exceeds the survival rate of commercial cryopreservation reagent.
Example 5 cryopreservation of bovine Kidney cells by LEA protein functional Domain Polypeptides
1. Material
Bovine kidney cells (MDBK) cells: purchased from Shanghai Xinyu Biotech, Inc.
Commercial vitrified cryopreservation solution containing 10% DMSO: purchased from Beijing Baicao Take Biotech Ltd.
2. Method of producing a composite material
(1) Preparation of cryopreservation solution and comparative example
The composition and preparation method of the cryopreservation liquids 1 to 4 are as described in example 2.
(2) MDBK cells preserved by the above cryopreservation liquid and comparative example formula
The specific operation method comprises the following steps: MDBK cells in T75 flasks were digested with 0.25% trypsin at 37 ℃ for 3min, neutralized by 2 volumes of complete medium (DMEM + 10% FBS) after the cells were dispersed into single cells and partially detached from the petri dish, pipetted until the cells were completely detached from the petri dish, transferred to a 15mL centrifuge tube, and centrifuged at 1400rpm for 5 min. The supernatant was discarded and the MDBK cells were resuspended using 5mL of DPBS. Cell counting and cell viability assays were performed using a cytometer. The number of cryopreserved cells in each centrifuge tube was 5 x 105And (4) respectively. The cell suspension was transferred to a cryopreservation tube (about 200. mu.L) according to the number of cells, and the cryoprotectant solution to be tested was added to the tubes respectively until the total volume was 400. mu.L. And (3) blowing, beating and uniformly mixing, putting the freezing tube into a program cooling box, freezing for 7 hours in a refrigerator at the temperature of minus 80 ℃, taking out the freezing tube, and transferring into a liquid nitrogen tank.
And (3) thawing the cells:
the above-described cryopreserved MDBK was removed from the liquid nitrogen tank, immediately placed in a 37 ℃ water bath, and shaken in the water bath to rapidly thaw the cells within 3 min. Then 100 μ L of the thawed cell suspension is taken out for cell counting and cell survival rate detection. The remaining 400. mu.L was added to 2.5 volumes of complete medium (DMEM + 10% FBS) and then transferred to a 1.5mL centrifuge tube and centrifuged at 1400rpm for 5 min. The supernatant was discarded and the cells were resuspended using 400. mu.L of PBS. Cell counting and cell viability detection (viability ═ number of viable cells/total number of cells) were performed using a cytometer.
3. Results and conclusions
TABLE 6 cryopreservation of bovine kidney cell viability
As can be seen from the results in table 6, the cryopreservation solution prepared from the LEA functional domain polypeptide as the main component has a high survival rate when used for cryopreservation of the cell line bovine kidney cells, which indicates that the cryopreservation reagent based on the protein functional domain of LEA can not only achieve the effectiveness of the conventional cryopreservation solution for cryopreservation of the cell line bovine kidney cells, but also the cryopreservation solution 3 has a recovery rate (no statistical difference) equivalent to that of the currently widely used commercial cryopreservation solution containing 10% DMSO.
Example 6 cryopreservation of human acute T-lymphocytic leukemia cells by LEA protein functional region Polypeptides
1. Material
Human acute T-lymphocyte leukemia cell (E6-1 cell): purchased from Wuhan Punuoise Biotech, Inc.;
commercial vitrified cryopreservation solution containing 10% DMSO: purchased from Beijing Baicao Take Biotech Ltd.
2. Method of producing a composite material
(1) Preparation of a cryopreservation solution:
the composition ratios and preparation methods of the cryopreservation liquids 1 to 4 were as described in example 2.
(2) Human acute T lymphocyte is preserved by using the cryopreservation liquid and the formula of the comparative example
The cryopreservation method of human acute T lymphocytes used in the invention is specifically the same as the CHO cryopreservation method, see the method in example 4.
3. Results and conclusions
TABLE 7 cryopreservation of human acute T-lymphocyte leukemia cell survival rates
According to the results in table 7, it can be seen that the cryopreservation solution prepared by using the LEA functional domain polypeptide as the main component has a high survival rate when used for cryopreservation of human acute T lymphocytes, which indicates that the cryopreservation reagent based on the protein functional domain of LEA can not only achieve the effectiveness of the human acute T lymphocytes of the conventional cryopreservation solution, but also achieve the equivalent (no statistical difference) survival rate to that of the currently widely used commercial cryopreservation solution containing 10% DMSO, and even exceed the survival rate of the commercial cryopreservation reagent.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A polypeptide comprising the amino acid sequence of a functional region of a LEA protein, or an active fragment, analogue or derivative of a polypeptide thereof. Preferably, the polypeptide is a functional region of a LEA protein.
2. The polypeptide of claim 1, wherein the polypeptide is selected from at least one of the following a) to c):
a) having the amino acid sequence shown in table 1;
b) a derivative polypeptide which is formed by deleting or adding one or more amino acids from both ends of a polypeptide having an amino acid sequence shown in Table 1 and has a function of a) the polypeptide; or
c) The homology is higher than 90% compared to the polypeptides of the amino acid sequences shown in table 1.
Preferably, in said c), said homology is between 90-99%, such as 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% compared to the polypeptides of the amino acid sequences shown in table 1.
Preferably, the amino acid sequence of the polypeptide is as shown in table 1.
More preferably, the amino acid sequence of the polypeptide is as shown in table 2.
3. A polynucleotide, characterized in that the polynucleotide comprises one selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide having an amino acid sequence set forth in table 1, or a fragment, analog, derivative thereof;
(b) a polynucleotide complementary to polynucleotide (a); or
(c) A polynucleotide sharing at least 70% identity to (a) or (b).
Preferably, the polynucleotide comprises a polynucleotide encoding a polypeptide having an amino acid sequence as set forth in table 1.
More preferably, the polynucleotide encodes a polypeptide as shown in table 1.
More preferably, the polynucleotide encodes a polypeptide as shown in table 2.
4. Use of a polypeptide according to claim 1 or 2 for cryopreservation of cells, tissues or organs.
Preferably, the polypeptide may be used in combination with other ice-controlling materials selected from at least one of amino acids, polyamino acids or saccharides.
5. A cryopreservation solution comprising the polypeptide of 1 or 2.
Preferably, the frozen preservation solution contains 0.1-50g of the polypeptide, 5.0-45mL of polyalcohol and 0.1-1.0mol L of water-soluble sugar per 100mL of frozen preservation solution-10-30mL of serum and the balance of buffer solution;
preferably, the bionic ice control material is one or more than two of amino acid monomers, polyamino acid or saccharides;
preferably, it may also contain serum;
preferably, the polyamino acid is selected from at least one homopolymer of lysine, arginine, proline, threonine, histidine, etc., or a copolymer of two or more amino acids;
preferably, the polyhydric alcohol is a polyhydric alcohol having 2 to 5 carbon atoms, such as any of ethylene glycol, propylene glycol, and glycerin;
preferably, the water-soluble sugar is at least one of non-reducing disaccharide, water-soluble polysaccharide and anhydrosugar, and is selected from sucrose, trehalose, water-soluble cellulose (e.g., hydroxypropyl methylcellulose, etc.), polysucrose;
preferably, the buffer is selected from at least one of DPBS or hepes-buffered HTF buffer or other cell culture medium buffer;
preferably, the serum is selected from human serum albumin or a substitute thereof for human-derived cryopreserved subjects, such as Sodium Dodecyl Sulfate (SDS); fetal bovine serum or bovine serum albumin can be selected for the non-human-derived cryopreservation object.
6. The cryopreservation solution of claim 5, wherein the cryopreservation solution comprises 0.1 to 50g of the polypeptide of claim 1 or 2, 0 to 9.0g of the amino acid monomer or saccharide, 0 to 15mL of DMSO, 0 to 45mL of the polyol, and 0.1 to 1.0mol of L per 100mL of the cryopreservation solution-10-30mL of serum, 0-30mL of glycol and the balance of buffer solution.
Preferably, the cryopreservation solution comprises 1.0g of the polypeptide of claim 1 or 2, 10-15mL of ethylene glycol, and 0.5mol L per 100mL-1Sucrose and the balance buffer solution.
Preferably, the cryopreservation solution comprises 0.5g of the polypeptide of claim 1 or 2, 0.8-1.0g of L-Pro, 10mL of ethylene glycol, and 0.5mol of L per 100mL-1The balance being buffer solution.
Preferably, the cryopreservation solution comprises, per 100mL, 0.5g of the polypeptide of claim 1 or 2, 0.8-1.0g of L-Pro8, 10mL of ethylene glycol, 0.5mol L-1The balance being buffer solution.
Preferably, the cryopreservation solution comprises 0.5g of the polypeptide of claim 1 or 2, 1.0g of glucose, 10mL of ethylene glycol, and 0.5mol L per 100mL-1The balance being buffer solution.
7. A method of preparing a cryopreservation liquid according to claim 5 or 6, comprising dissolving the polypeptide in a buffer, adjusting the pH after cooling to room temperature, dissolving the other components in a further buffer, mixing after cooling, adjusting the pH, bringing to a predetermined volume with the buffer, optionally adding serum at the time of use,
preferably, the method comprises the following steps:
(1) dissolving polypeptide in a part of buffer solution, cooling to room temperature, and adjusting pH to obtain a solution 1;
(2) dissolving water-soluble sugar in a part of buffer solution, and adding other components after the water-soluble sugar is completely dissolved to prepare a solution 2;
(3) optionally, dissolving the amino acid monomer and/or the saccharide in another part of the buffer solution, cooling to room temperature, and adjusting the pH value to obtain a solution 3;
(4) and (3) cooling the solution 1, the solution 2 and optionally the solution 3 to room temperature, mixing, adjusting the pH value, and fixing the volume to a preset volume by using a buffer solution to obtain the cryopreservation solution.
8. Use of the cryopreservation solution of claim 5 or 6 for cryopreservation of cells, tissues or organs.
Preferably, the cryopreservation liquid of claim 5 or 6 is used in combination with an ice control material.
9. A cryopreservation method for cryopreserving cells, tissues or organs using the cryopreservation liquid according to claim 5 or 6.
Preferably, the cryopreservation method comprises the following steps: and placing the cells and tissues to be cryopreserved in the cryopreservation liquid, and then placing the cells and tissues in a liquid nitrogen environment for cryopreservation.
More preferably, the cryopreservation can adopt two methods of slow cooling and fast cooling.
Preferably, the cryopreservation method further comprises thawing: taking out the frozen cells and tissues from the liquid nitrogen environment, and quickly putting the cells and tissues into a water bath at 37 ℃ for thawing. Thawed cells, tissues are washed with culture medium or PBS and transferred to a suitable culture environment as soon as possible.
10. The use according to claim 4 or 8 or the cryopreservation method of claim 9 wherein the cell, tissue or organ is any cell, tissue or organ suitable for cryopreservation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210043367.6A CN114539382A (en) | 2022-01-14 | 2022-01-14 | Polypeptide and cryopreservation liquid containing polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210043367.6A CN114539382A (en) | 2022-01-14 | 2022-01-14 | Polypeptide and cryopreservation liquid containing polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114539382A true CN114539382A (en) | 2022-05-27 |
Family
ID=81671422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210043367.6A Withdrawn CN114539382A (en) | 2022-01-14 | 2022-01-14 | Polypeptide and cryopreservation liquid containing polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114539382A (en) |
-
2022
- 2022-01-14 CN CN202210043367.6A patent/CN114539382A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102502294B1 (en) | Compositions and methods for maintaining cell viability | |
| Jang et al. | Cryopreservation and its clinical applications | |
| CN108207930B (en) | Cocktail type cryoprotectant and application thereof | |
| KR102196974B1 (en) | Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation | |
| CN106922648A (en) | A kind of mescenchymal stem cell cryopreservation solution and preparation method thereof | |
| CN111789105B (en) | Application of amino acid cryopreservation liquid in stem cell cryopreservation | |
| JP6561173B2 (en) | Mammalian cell administration solution | |
| CN111793110B (en) | Application of DMSO-free cryopreservation liquid in stem cell cryopreservation | |
| CN111789104B (en) | Application of cryopreservation liquid in stem cell cryopreservation | |
| CN114467917A (en) | Application of cryopreservation liquid containing polypeptide in cryopreservation of engineering cells and cell lines | |
| CN114539382A (en) | Polypeptide and cryopreservation liquid containing polypeptide | |
| CN115005199B (en) | Freezing solution, freezing method and application of natural killer cells | |
| CN114451400A (en) | Application of cryopreservation liquid containing polypeptide in stem cell cryopreservation | |
| JP7459130B2 (en) | Melt liquid and its preparation method and application | |
| US11998002B2 (en) | Cryopreserving processes | |
| CN111789102B (en) | Application of thawing solution in thawing frozen and preserved oocyte or embryo | |
| Ali et al. | Chapter-8 Cryopreservation procedure: An emerging trend in human reproduction system | |
| EP3764785A1 (en) | Cryopreserving processes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220527 |
|
| WW01 | Invention patent application withdrawn after publication |